<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">48822</article-id><article-id pub-id-type="doi">10.7554/eLife.48822</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Crystal structure of dopamine receptor D4 bound to the subtype selective ligand, L745870</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-148295"><name><surname>Zhou</surname><given-names>Ye</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0489-3614</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-148296"><name><surname>Cao</surname><given-names>Can</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" id="author-148297"><name><surname>He</surname><given-names>Lingli</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-148298"><name><surname>Wang</surname><given-names>Xianping</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-29580"><name><surname>Zhang</surname><given-names>Xuejun Cai</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6726-3698</contrib-id><email>zhangc@ibp.ac.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules</institution><institution>Institute of Biophysics, Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>University of Chinese Academy of Sciences</institution><addr-line><named-content content-type="city">Beijing</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Boudker</surname><given-names>Olga</given-names></name><role>Senior Editor</role><aff><institution>Weill Cornell Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>21</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e48822</elocation-id><history><date date-type="received" iso-8601-date="2019-05-27"><day>27</day><month>05</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-11-06"><day>06</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Zhou et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Zhou et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-48822-v1.pdf"/><abstract><p>Multiple subtypes of dopamine receptors within the GPCR superfamily regulate neurological processes through various downstream signaling pathways. A crucial question about the dopamine receptor family is what structural features determine the subtype-selectivity of potential drugs. Here, we report the 3.5-angstrom crystal structure of mouse dopamine receptor D4 (DRD4) complexed with a subtype-selective antagonist, L745870. Our structure reveals a secondary binding pocket extended from the orthosteric ligand-binding pocket to a DRD4-specific crevice located between transmembrane helices 2 and 3. Additional mutagenesis studies suggest that the antagonist L745870 prevents DRD4 activation by blocking the relative movement between transmembrane helices 2 and 3. These results expand our knowledge of the molecular basis for the physiological functions of DRD4 and assist new drug design.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>GPCR</kwd><kwd>ligand binding</kwd><kwd>antagonist</kwd><kwd>DRD4</kwd><kwd>dimerization</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002367</institution-id><institution>Chinese Academy of Sciences</institution></institution-wrap></funding-source><award-id>Strategic Priority Research Program XDB08020301</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Xuejun Cai</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003711</institution-id><institution>Ministry of Science and Technology</institution></institution-wrap></funding-source><award-id>2015CB910104</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Xuejun Cai</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31470745</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Xuejun Cai</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The structure of receptor-ligand complex reveals the ligand binding selectivity among different dopamine receptor subtypes and also shows how this ligand class inhibits receptor activity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Dopamine and its receptors play fundamental roles in controlling neurological processes including motor control, cognition, learning, and emotions (<xref ref-type="bibr" rid="bib4">Beaulieu and Gainetdinov, 2011</xref>). Dopaminergic dysfunction is associated with the pathophysiology of various disorders such as schizophrenia, mood disorders, attention-deficit disorder, Tourette's syndrome, substance dependency, and Parkinson's disease (<xref ref-type="bibr" rid="bib23">Girault and Greengard, 2004</xref>). The dopamine receptor family, which belongs to the G-protein-coupled receptor (GPCR) superfamily, can be divided into two subfamilies, namely the D1-like subfamily (including dopamine receptor D1 (DRD1) and DRD5), and the D2-like subfamily (including DRD2, DRD3, and DRD4). These subfamilies probably originated from two independent acquirements of the ability of dopamine binding during the evolution of biogenic amine receptors (<xref ref-type="bibr" rid="bib42">Opazo et al., 2018</xref>). The D1- and D2-like subfamilies are coupled to different G proteins, activating distinct downstream signaling pathways (<xref ref-type="bibr" rid="bib39">Neve et al., 2004</xref>). In particular, DRD1 and DRD5 are found exclusively in postsynaptic sites of dopamine-receptive neurons. After binding dopamine, they activate Gα<sub>s/olf</sub> proteins and upregulate the adenylyl cyclase activity in the cell. In comparison, DRD2, DRD3, and DRD4 are expressed both presynaptically on dopaminergic neurons and postsynaptically on dopamine target cells. They activate Gα<sub>i/o</sub> proteins and thus downregulate the adenylyl cyclase activity (<xref ref-type="bibr" rid="bib56">Sokoloff, 2006</xref>; <xref ref-type="bibr" rid="bib46">Rondou et al., 2010</xref>).</p><p>Recent advances in GPCR structure biology make it possible to solve the mystery of dopamine receptors and their signaling pathways. To date, the structures of all three types of D2-like receptors have been reported: In 2010, the crystal structure of human DRD3 was solved (<xref ref-type="bibr" rid="bib13">Chien et al., 2010</xref>), followed by crystal structures of human DRD4 (<xref ref-type="bibr" rid="bib63">Wang et al., 2017</xref>) and DRD2 (<xref ref-type="bibr" rid="bib64">Wang et al., 2018</xref>). In agreement with their high degree of sequence homology, ligand-binding pockets in these D2-like receptors share many structural features in addition to their conserved overall folding. These structural studies expand our understanding of the distinctive selectivity spectrum of the binding pockets of dopamine receptors toward different ligands including those belonging to the same chemical category but containing subtle modifications.</p><p>DRD4 is characterized by its more selective expression pattern in the brain (such as the frontal cortex and amygdala; <xref ref-type="bibr" rid="bib38">Murray et al., 1995</xref>), and thus exhibits promising pharmacological properties. Their anatomical localization in the prefrontal cortex, in contrast to little or no expression in the basal ganglia, strongly indicates roles of DRD4 receptors in cognition and emotions. Although dopamine is the most potent endogenous ligand known to activate DRD4, the receptor is also readily activated by epinephrine and norepinephrine (<xref ref-type="bibr" rid="bib40">Newman-Tancredi et al., 1997</xref>). In addition, clozapine binds to DRD4 with an affinity 10-fold higher than that to other dopaminergic receptors (<xref ref-type="bibr" rid="bib6">Boeckler et al., 2004</xref>; <xref ref-type="bibr" rid="bib65">Wilson et al., 1998</xref>). To date, the highest degree of selectivity for dopaminergic receptors having been achieved by pharmaceutics are certain DRD4-selective antagonists, exhibiting more than 1000-fold higher affinity towards D4 receptors compared to other dopaminergic receptors (<xref ref-type="bibr" rid="bib46">Rondou et al., 2010</xref>). One well-characterized selective DRD4-antagonist with high affinity (K<sub>i</sub> ~0.43 nM) is a 1,4-disubstituted aromatic piperidine/piperazine (1,4-DAP) compound named L745870 (<xref ref-type="bibr" rid="bib43">Patel et al., 1997</xref>). L745870 has been extensively analyzed for its pharmacology in various behavioral tests (in rodents) and clinical trials for treating schizophrenia (<xref ref-type="bibr" rid="bib43">Patel et al., 1997</xref>; <xref ref-type="bibr" rid="bib8">Bristow et al., 1997</xref>).</p><p>To facilitate future pharmacological studies and possible improvement of related compounds, we determined the 3.5 Å resolution crystal structure of mouse DRD4 (66% identical to the human DRD4 in the whole amino acid sequence and 89% identical in the transmembrane (TM) region) in complex with L745870. This complex structure shows the existence of an extended ligand-binding pocket specific for DRD4s and improved our understanding of the structural bases of subfamily-selectivity of potential antagonists.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Overall structures</title><p>To crystallize the mouse DRD4 (simply referred to as DRD4 hereafter unless otherwise specified), we used protein engineering (<xref ref-type="bibr" rid="bib16">Chun et al., 2012</xref>; <xref ref-type="bibr" rid="bib10">Cao et al., 2018</xref>) in combination with lipidic cubic phase (LCP) methods (<xref ref-type="bibr" rid="bib9">Caffrey, 2009</xref>). Recombinant proteins were purified and crystallized in the presence of the subtype-selective antagonist, L745870, to stabilize the receptor (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). To aid crystallization, we replaced the long, presumably disordered, intracellular loop 3 (ICL3, that is residues A220<sup>5.70</sup>–A302<sup>6.24</sup>) of the receptor with a thermo-stable variant of apocytochrome b<sub>562</sub> (BRIL) (<xref ref-type="bibr" rid="bib16">Chun et al., 2012</xref>). To improve the diffraction quality of the DRD4 crystal, we truncated the N-terminal 22 amino acid residues, which fail to adopt an ordered secondary structure according to bioinformatic predictions. This N-terminal peptide was replaced by a FLAG-tag without interfering with the overall structure. To the contrary, the tag appeared to facilitate the crystallization process. The crystallized recombinant DRD4 protein contained four additional point mutations, F121<sup>3.41</sup>W, P201<sup>5.52</sup>I, P317<sup>6.38</sup>A, and C181<sup>45.51</sup>R (superscript numerals refer to the Ballesteros-Weinstein numbering system; <xref ref-type="bibr" rid="bib3">Ballesteros and Weinstein, 1995</xref>). The first mutation is based on a previously reported stabilizing mutation in class-A GPCRs (<xref ref-type="bibr" rid="bib47">Roth et al., 2008</xref>) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). The remaining three mutations were designed based on sequence comparison of the D2-like subfamily (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>) and were predicted not to impair the native binding ability of the receptor. In particular, P201<sup>5.52</sup>I and P317<sup>6.38</sup>A were found to be necessary for proper crystallization, while C181<sup>45.51</sup>R improved the diffraction quality. The combination of these modifications (including the BRIL fusion) increased the melting temperature (Tm) of the protein variant by 13°C compared to the wild-type protein (WT, without the ICL3 substitution), and the presence of L745870 further increased the Tm by 20°C (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>). The DRD4 crystal structure was refined at 3.5 Å resolution (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Furthermore, a recently reported technique utilizes a cpGFP (circular permuted GFP)-fusion dopamine receptor variant as an in vivo dopamine-binding reporter (<xref ref-type="bibr" rid="bib44">Patriarchi et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Sun et al., 2018</xref>). Based on this method, we confirmed that the mutation variant used for structural determination (with BRIL replaced by cpGFP) maintained significant ability to response to both agonists and antagonists (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>).</p><p>The overall structure of the TM domain of mouse DRD4 was similar to the previously reported ground-state structures of human DRD4 and DRD3 (<xref ref-type="bibr" rid="bib13">Chien et al., 2010</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2017</xref>). Our DRD4 crystal possessed a typical type-I crystal packing of membrane proteins, with the TM regions forming continuous layers. Moreover, DRD4 formed a non-symmetrical dimer in each crystallography asymmetric unit. The two protomers are denoted as Mol-A and Mol-B, and are related to each other by a 44° rotation about an axis perpendicular to the membrane plane in addition to a non-crystallographic translation (<xref ref-type="fig" rid="fig1">Figure 1a,b</xref>). TMs 5 and 6 of the receptor form continuous helices with a helix pair from the helix bundle of the BRIL fusion. This intact helix structure seems to provide more rigid packing which may explain why the P201<sup>5.52</sup>I and P307<sup>6.38</sup>A mutations facilitated crystallization. Structures of the FLAG-tag and N-terminal residues 23–30 failed to be resolved, presumably due to their flexibility or multiple conformations. Well-defined electron densities were observed for ICL1, extracellular loop-1 (ECL1), and ECL3. In contrast, electron density of ECL2 in Mol-B broke near the signature C105<sup>3.25</sup>-C180<sup>45.50</sup> disulfide bond, and residues between the C-terminal end of TM4 and the conserved C180<sup>45.50</sup> were unsolvable from the density. In comparison, the ECL2 of Mol-A showed a clear electron density at the C-terminal end of TM4, but became disordered near the N-terminal end of TM5. This stability difference between the two ECL2 loops is likely to be due to distinct crystal packing interactions (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplements 3</xref> and <xref ref-type="fig" rid="fig1s4">4</xref>). Based on the quality of the electron density map as well as the distribution of B-factors (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>), the most stable regions of the entire dimer were the dimer interface and BRIL helices fused with TMs 5 and 6 in Mol-B. Thus, the dimer appeared to serve as a structural unit of crystal packing. In comparison, the BRIL molecule fused with Mol-A exhibited a higher flexibility. The C-termini of the both protein molecules were also disordered, with only a short segment of helix-8 being resolved in each protomer.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>The overall structure of mouse DRD4 in complex with L745870.</title><p>(<bold>a</bold>) Ribbon representation of mouse DRD4 (TM domain presented in cyan, ligand in yellow, and BRIL fusion in orange), as viewed parallel to the membrane with approximate membrane boundaries indicated with gray lines. (<bold>b</bold>) Top view of the mouse DRD4 structure. Rotation angle between Mol-A and Mol-B calculated with PyMOL is shown as a red angle sign. (<bold>c</bold>) The L745870 antagonist is shown in stick representation with carbon, nitrogen and chloride atoms shown in yellow, blue, and green, respectively. Fo−Fc omit density map for L745870 is contoured at 2.5 σ. (Also see <xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>) (<bold>d</bold>) Chemical structure of L745870.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Profiles of DRD4 in different constructs or under different conditions.</title><p>(<bold>a</bold>) The ThermoFluor (<xref ref-type="bibr" rid="bib2">Alexandrov et al., 2008</xref>) and monodispersity validation of different constructs of DRD4. The melting temperature (Tm) of WT is approx. 43°C (i, blue curve, solid line, Boltzmann sigmoid fitting, dashed line, experimental data), and the F3.41W mutation construct elevated Tm ~5°C (panel i, red curve). Tm of the BRIL-fusion protein reached above 50°C (panel ii, black curve), and when it was incubated with DRD4 ligands Tm was raised above 70°C (ii, colored curves). The size exclusion chromatography assay with nanofilm SEC-250 (Sepax Technologies) shows that the monodispersity of the fusion protein (panel iii) was improved differently with different ligands. 0: no ligands during purification; 1: thioridazine (<xref ref-type="bibr" rid="bib52">Seeman and Lee, 1975</xref>) (Sigma-Aldrich); 2: ABT-724 (<xref ref-type="bibr" rid="bib7">Brioni et al., 2004</xref>) (Tocris); 3: (-)quinpirole (<xref ref-type="bibr" rid="bib36">Millan et al., 2002</xref>) (Tocris); 4: PD-168568 (<xref ref-type="bibr" rid="bib5">Belliotti et al., 1998</xref>) (Tocris); 5: Mesoridazine (<xref ref-type="bibr" rid="bib14">Choi et al., 2004</xref>) (Sigma-Aldrich); 6: Fananserin (<xref ref-type="bibr" rid="bib60">Truffinet et al., 1999</xref>) (Sigma-Aldrich); 7: spiperone (<xref ref-type="bibr" rid="bib24">Hidaka et al., 1995</xref>) (Sigma-Aldrich); 8: L745870; and 9: L750667 (<xref ref-type="bibr" rid="bib49">Schetz et al., 2000</xref>) (Tocris). (<bold>b</bold>) The DRD4-L745870 complex shows a single peak in Superdex200 (R.V., retention volume). The Tm of the complex was determined as ~72°C. (<bold>c</bold>) Initial crystal images under different conditions (panels i–iv: visual light image) and optimized crystals (panel v: visual light image and polarized light image) used for data collection.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Protein sequence alignment of D2-like family members.</title><p>Red stars below the TM2 and TM3 sequences indicate the non-conserved residue position in the extended pocket. Black boxes show the mutations (P<sup>5.52</sup>I, P<sup>6.38</sup>A, and C<sup>45.51</sup>R) in TM5, TM6, and ECL2, which facilitated the crystallization. Triangles mark the binding residues of Nemonaride (blue) and L745870 (purple). Alignment was generated with <ext-link ext-link-type="uri" xlink:href="http://gpcrdb.org/">http://gpcrdb.org/</ext-link> website.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Crystal packing of the mouse DRD4.</title><p>The D4 dopamine receptor is shown in aquamarine, BRIL fusion protein is shown in brown, and L745870 is shown as yellow sphere models. The blue box depicts the crystallography unit cell.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Interactions of different asymmetric units in mouse DRD4 crystal packing.</title><p>Head-to-head interactions through hydrophobic packing. P341 and F344 in ECL3 of Mol-B interacts with P173 in ECL2 of Mol-A from a neighboring asymmetric unit. No ordered interaction was detected between the BRILs of Mol-A from neighboring asymmetric units, in agreement with high B factors in this region. Salt bridges stabilize the interaction between BRILs in Mol-B from neighboring asymmetric units, which mediate the packing force between two membrane layers. Residue numbers 1001–1106 were assigned from the N-terminus to C-terminus of BRIL, independently of the receptor.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>The B-factors distribution and representative electron density.</title><p>(<bold>a</bold>) B-factor putty representation of the mouse DRD4 structure. Blue-to-red rainbow spectrum is from the lowest (~30 Å<sup>2</sup>) to highest (&gt;200 Å<sup>2</sup>). b, c, d. Representative |2F<sub>o</sub>|–|F<sub>c</sub>| electron density map (deep purple and magenta contoured at 1.0 σ) of TM5 and TM6 (<bold>b</bold>) and ligand-binding pocket (<bold>c</bold>). Panel d shows a side-by-side stereo view of the ligand pocket in Mol-B. The green density represents |F<sub>o</sub>|–|F<sub>c</sub>| omit map of the ligand, contoured at 2.5 σ.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig1-figsupp5-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Ligand-binding pocket</title><p>Clear electron density was observed in the ligand-binding pocket in Mol-B; in comparison, the electron-density omit map was murky at the corresponding position in Mol-A (<xref ref-type="fig" rid="fig1">Figure 1c</xref>). Nevertheless, including L745870 in Mol-A in a conformation similar to that in Mol-B during refinement successfully reduced the R-factors, albeit only slightly. Because of the limited resolution of our crystal structure, we do not further speculate the biological significance of the differential binding of L745870 in the non-symmetrical dimer (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Here, we describe the binding pocket of DRD4 on the basis of L745870 bound to Mol-B. This antagonist was buried in the upper part of the TM core underneath the signature C105<sup>3.25</sup>-C180<sup>45.50</sup> disulfide bond (<xref ref-type="fig" rid="fig2">Figure 2a,b</xref>). The binding pocket was formed by residues from TMs 2, 3, 5, 6, and 7. Furthermore, L745870 is a typical 1,4-DAP compound (<xref ref-type="fig" rid="fig1">Figure 1d</xref>), which presents a common characteristic of many high-selectivity ligands of D4 receptors (<xref ref-type="bibr" rid="bib41">Oak et al., 2000</xref>). A proton-titratable amine group exists in the core piperazine on the arm side of the heterocyclic ring (<xref ref-type="bibr" rid="bib31">Kortagere et al., 2004</xref>), and formed a hydrogen bond (2.9 Å) with the acidic residue, D112<sup>3.32</sup>, conserved in all members of the aminergic receptor family. Simultaneously, the carboxyl sidechain of D112<sup>3.32</sup> formed a hydrogen bond with the hydroxyl group of Y358<sup>7.43</sup>, and this hydrogen bond is also conserved in almost all aminergic receptor structures (<xref ref-type="bibr" rid="bib63">Wang et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Wang et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Liu et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Chung et al., 2011</xref>; <xref ref-type="bibr" rid="bib59">Thal et al., 2016</xref>). D112<sup>3.32</sup> serves as the counter ion for the protonated amine group in neurotransmitters such as dopamine, serotonin, and epinephrine (<xref ref-type="bibr" rid="bib61">van Rhee and Jacobson, 1996</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Molecular details of the L745870-binding site in DRD4.</title><p>(<bold>a</bold>) Mesh (Mol-A) and surface (Mol-B) representation of mouse DRD4 as viewed parallel to the membrane plane, clipped to reveal L745870 (colored as in <xref ref-type="fig" rid="fig1">Figure 1</xref>). (<bold>b</bold>) Interactions between the residues confining the binding pocket and L745870 (shown in magenta), with potential polar interactions depicted as dashed red lines. (<bold>c, d</bold>) Top view of surface representation of binding pocket in DRD2/3 and DRD4, respectively. L745870 is colored as in <xref ref-type="fig" rid="fig1">Figure 1</xref>. (<bold>e</bold>) Structural differences in the extended binding pockets (EBPs) of DRD4 (cyan), DRD2 (gray), and DRD3 (magenta). L745870 is shown as a space-filling model with carbon, nitrogen, and chloride atoms shown in cyan, blue, and green, respectively. (<bold>f</bold>) Comparison of nemonapride and L745870 in 3D models as well as 2D structures. The protonatable amino groups are marked with dashed lines in the 2D structures. For nemonapride, protonation occurs both at positions 1 and 2, whereas for L745870 it occurs mainly at position 1. The 3D steric conformations were generated with Maestro using the ligand preparation mode.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Representative results from Ligand binding-induced fluorescence intensity change with DRD4-cpGFP based dopamine assay.</title><p>(<bold>a</bold>) Fluorescence intensity of the WT* and ‘crystallization’ construct. The signals changed with different agonists or L745870 (labeled as L-7) at varied concentrations. Full length DRD4 with its ICL3 replaced with cpGFP is denoted here as WT*, and a similar cpGFP fusion but also containing mutations and truncations as the crystallization construct is labeled as ‘Crystal’. Events of addition of dopamine (DA) are depicted with green arrows; L-7, blue arrows; and quinpirole (Quin, an agonist of the D2-like subfamily), purple arrows. The reported fluorescence intensity (in arbitrary unit) is the mean value of all pixels within a selected area containing the cell(s) of interests. (<bold>b</bold>) Mutations in the orthosteric binding pocket. The mutation S<sup>5.42</sup>A lowered the dopamine activating ability, S<sup>5.46</sup>A eliminated the dopamine signal, and S<sup>5.43</sup>A showed no effect to dopamine response. In comparison, the mutation F<sup>6.51</sup>Y showed higher sensitivity to ligands used. (<bold>c</bold>) Mutations in the extending binding pocket. The mutations of S<sup>2.64</sup>L and L<sup>3.28</sup>F abolished the inhibition ability of L745870, yet S<sup>2.64</sup>F eliminated the dopamine signal all together. (<bold>d</bold>) Examples of confocal images of HEK cells either bathed in PBS or with additional dopamine.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Structural comparison of mouse and human DRD4 receptors.</title><p>(<bold>a</bold>) Structural superposition of Mol-A and Mol-B of mouse DRD4 with human DRD4 (PDB ID: 5WIU). No significant conformational shift was observed around the binding pocket among the three structures. (<bold>b</bold>) Small outward shift of TM5 and TM6 in mouse DRD4 relative to human DRD4 may be explained by the BRIL conformation/crystal packing. Similar packing was observed in the A2A receptor structure (PDB ID: 4EIY).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig2-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Orthosteric pocket</title><p>The heterocyclic ring of L745870 resides in the relatively hydrophobic orthosteric pocket, surrounded by V113<sup>3.33</sup>, F330<sup>6.51</sup>, and F331<sup>6.52</sup> from both sides, and by C116<sup>3.36</sup> and W327<sup>6.48</sup> from the bottom. In our cpGFP-based dopamine-activation assay, the F330<sup>6.51</sup>Y mutation, which left the aromatic moiety unchanged, showed no detectable defect on the binding of dopamine or other ligands used (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>).</p><p>The well-conserved residues S191<sup>5.42</sup> and S192<sup>5.43</sup>, which are postulated to function as hydrogen-bond acceptors for the hydroxyl groups of bioamines during dopamine activation (<xref ref-type="bibr" rid="bib57">Strader et al., 1989</xref>; <xref ref-type="bibr" rid="bib18">Cox et al., 1992</xref>), were found to be positioned away from L745870 in our complex structure, probably because of the lack of hydroxyl groups in the pyridine part of the ligand. Moreover, our cpGFP-based dopamine-activation assay (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1b</xref>) showed that, to induce the fluorescence intensity change (<italic>i.e.</italic>, to activate the receptor), the S191<sup>5.42</sup>A -containing variants required 100-fold higher concentrations of dopamine compare to the WT construct. In comparison, the S192<sup>5.43</sup>A mutation slightly interfered with the dopamine-induced conformational change. In addition, the S195<sup>5.46</sup>A mutation completely abolished the activating ability of dopamine. In agreement with previous reports (reviewed in <xref ref-type="bibr" rid="bib35">Michino et al., 2015</xref>), our functional studies suggest that the three adjacent serine residues within the orthosteric pocket play crucial roles in receptor activation by dopamine.</p></sec><sec id="s2-4"><title>Extended pocket</title><p>The chlorophenyl arm of L745870 was observed to protrude into an extended pocket of our mouse DRD4 structure, which is also present in the human DRD4 structure (<xref ref-type="bibr" rid="bib63">Wang et al., 2017</xref>). In particular, the ligand-binding pocket of DRD4 extended from the orthosteric pocket into a crevice between TM2 and TM3, rather than a crevice between TM2 and TM7 as observed in the D2 and D3 receptors (<xref ref-type="fig" rid="fig2">Figure 2c,d</xref>). This extended pocket was surrounded by residues L83<sup>2.56</sup>, F88<sup>2.61</sup>, S91<sup>2.64</sup>, L108<sup>3.28</sup>, and M109<sup>3.29</sup>, with the signature C105<sup>3.25</sup>-C180<sup>45.50</sup> disulfide bond and W98<sup>23.50</sup> (a conserved residue in the connecting loop between TMs 2 and 3) located on the top of the pocket. However, a few structural features around TM2 appear to limit further extension of the pocket. For instance, while providing hydrophobic interactions with the piperazine group of L745870, F88<sup>2.61</sup> obstructed further extension. Similarly, a hydrogen bond between E92<sup>2.65</sup> and S351<sup>7.36</sup> appeared to function as a lock restricting the extension (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). In agreement with these structural observations, our cpGFP-based dopamine-activation assays showed that small-to-large mutations S91<sup>2.64</sup>L and L108<sup>3.28</sup>F dramatically reduced the inhibitory effects of L745870 against dopamine activation. Even more drastically, the S91<sup>2.64</sup>F mutation abolished the response of the receptor to dopamine (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c</xref>).</p></sec><sec id="s2-5"><title>Dimerization</title><p>Our crystal structure of DRD4 revealed a non-symmetrical interface between TMs 1–3 of Mol-A and TMs 5 and 6 of Mol-B. Following dimerization, a total of 1600 Å<sup>2</sup> ‘solvent-accessible surface’ was buried within the dimer. To our knowledge, such a non-symmetrical homodimer has not been described in crystal structures of GPCRs before. The dimerization was stabilized by hydrogen bonds from both extracellular and intracellular regions, as well as hydrophobic packing between the transmembrane domains (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). In particular, a polar interaction between S101<sup>A3.21</sup> and D186<sup>B5.37</sup> (the superscript letter, A or B, denotes the host protomer of the corresponding residue) linked the extracellular sides of TM3<sup>A</sup> and TM5<sup>B</sup>, whereas a hydrophobic interaction on the same side of TM2<sup>A</sup> and TM6<sup>B</sup> was formed through Y90<sup>A2.63</sup> and L339<sup>B6.60</sup>, together with a disulfide bridge within ECL3 of Mol-B (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). On the intracellular side, two hydrogen bonds (namely between the mainchain of A57<sup>A1.58</sup> and the sidechain of T135<sup>B3.55</sup>, and between the sidechain of S58<sup>A1.59</sup> and the mainchain of G213<sup>B5.64</sup>) and a salt-bridge bond between E59<sup>A1.60</sup> and R216<sup>B5.67</sup> stabilized the packing of TM1<sup>A</sup>, TM3<sup>B</sup>, and TM5<sup>B</sup> (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). These interacting regions formed a stabilizing triangle, locking the dimer interface of aliphatic interactions of the TM region in a stable conformation. Results from our cross-linking experiment further suggest that dimerization of recombinant DRD4 molecules also occurs in solution (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Interface details of mouse DRD4 in the asymmetric dimer.</title><p>(<bold>a</bold>) Overview of the interface of the mouse DRD4 dimer. Dot representations of the interacting residues are shown for the transmembrane domain (gray) and exo-membrane regions (colored). (b, c) Extracellular and intracellular faces of the DRD4 dimer. Red dashed lines depict potential polar interactions.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>DRD4 cross-linked with glutaraldehyde.</title><p>(<bold>a</bold>) SDS-PAGE of DRD4 sample cross-linked with a concentration gradient of glutaraldehyde (GA). Bands of protein dimers are clearly visible at 0.5 mM GA. (<bold>b</bold>) Detailed marker shows that the molecular weight of cross-linked band is approx. 80 kDa, which is twice the size of a DRD4 monomer.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-48822-fig3-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we present the structure analysis on DRD4 complexed with its antagonist L745870. Comparison of our complex structure with known structures of DRD2, DRD3, and DRD4 reveals the structural basis of subtype-selectivity (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). As suggested by previous reports (<xref ref-type="bibr" rid="bib55">Simpson et al., 1999</xref>; <xref ref-type="bibr" rid="bib49">Schetz et al., 2000</xref>), the subtype-specific determinants that contribute to the ligand selectivity within the D2-like subfamily are located near the extracellular ends of TMs 2 and 3. Receptors of this subfamily share the same set of residues in the orthosteric binding pocket to maintain dopamine binding ability. More importantly, less conserved residues in TMs 2 and 3 contribute micro-patches to the pocket that discriminates different substitutions of the ligands. For instance, in DRD2/3-antagonist complex structures, a smaller aliphatic sidechain at V<sup>2.61</sup> (compared to F88<sup>2.61</sup> in DRD4) allows ligands specific to the DRD2/3 subfamily to be oriented toward a crevice between TMs 1–2 and TM7 (<xref ref-type="bibr" rid="bib13">Chien et al., 2010</xref>). In addition, previous experiments substituting amino acid residues at less conserved positions in the D4 receptor with corresponding residues from DRD2 or constructing D2/D4 and D4/D2 hybrids with the chimeric junction located near the N-terminal portion of TM3 showed to switch the pharmacological profiles of the variants. In particular, DRD4-selective ligands showed decreased binding affinity to DRD4 variants constructed in such a manner (<xref ref-type="bibr" rid="bib31">Kortagere et al., 2004</xref>; <xref ref-type="bibr" rid="bib53">Shih et al., 1997</xref>). Importantly, steric clashes will occur at positions of S<sup>2.64</sup>L and L<sup>3.28</sup>F in DRD2/3 or W<sup>23.50</sup> in DRD2, if L745870 is superimposed into their corresponding ligand-binding pockets (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>From a pharmaceutical point of view, pluridimensional efficacy and adverse effects of a given drug result from its nonspecific interactions with unintended targets. Therefore, increasing the receptor-discriminating ability of lead compounds has long been a major focus of drug design and pharmaceutics. Ligands bound in the previously reported crystal structures of the D2, D3, and D4 receptors are risperidone, eticlopride, and nemonapride, respectively, all of which represent non-selective ligands. In particular, risperidone is known to bind to all D2-like receptors as well as other types of aminergic receptors (<xref ref-type="bibr" rid="bib28">Janssen et al., 1988</xref>); eticlopride is a DRD2/D3-selective antagonist (<xref ref-type="bibr" rid="bib29">Jensen, 2015</xref>); and nemonapride is both an antagonist of D2-like receptors and a potent agonist of the serotonin 1A (5-HT1A) receptor (<xref ref-type="bibr" rid="bib51">Seeman et al., 1993</xref>). Our crystal structure of the DRD4-L745870 complex provides a critical model to decipher the subtype selectivity of ligands, a characteristic of the D2-like receptors. Most classic biogenic amine ligands of aminergic receptors (agonists or antagonists, including L745870) possess a protonated amine group that binds the conserved D<sup>3.32</sup> site (<xref ref-type="bibr" rid="bib59">Thal et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Shimamura et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Ring et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Miller-Gallacher et al., 2014</xref>). This specific interaction partially explains why L745870 and dopamine compete for binding the DRD4. Furthermore, by reducing the moving freedom of TM3 required for full activation of class-A GPCRs (<xref ref-type="bibr" rid="bib27">Hulme, 2013</xref>), the bulky chemical group of L745870 inserted into the TM2-TM3 crevice may provide a structure basis for its antagonist activity. Being consistent with this notion, the results of our mutational analysis showed that, when substituting S<sup>2.64</sup> in the TM2-TM3 cavity with a bulky sidechain (such as Leu or Phe), the dopamine-induced activity was decreased or totally abolished (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). To further elaborate the discrepancy between the chemical structures of L745870 and nemonapride and its relationship to the binding modes inside DRD4, we performed a molecular docking analysis using the program Schrodinger (<xref ref-type="bibr" rid="bib22">Friesner et al., 2006</xref>). Under the same set of simulation conditions, a nemonapride molecule assumes up to 11 steric conformations with each containing two protonated sites; in contrast, two conformations are observed for L745870, and only one of them is able to form a hydrogen bond to D<sup>3.32</sup>(<xref ref-type="fig" rid="fig2">Figure 2f</xref>). Upon anchoring the central proton-titratable amino group of the ligand to D<sup>3.32</sup>, the more hydrophilic entity on one side occupies the dopamine-binding orthosteric pocket, while the more hydrophobic entity on the other side protrudes into the extended pocket. Torsion angles between the three parts appear to play important roles in determining the ligand-binding mode. These observations clearly explain why nemonapride can bind to both D4 and D2/3 receptors whereas L745870 possesses high selectivity toward the D4 receptor, thus suggesting a direction to improve the ligand potency for the D2-like subfamily.</p><p>GPCR oligomerization has been proposed to modulate trafficking, cooperativity of ligand-binding, and signaling efficacy (<xref ref-type="bibr" rid="bib21">Farran, 2017</xref>). Accumulating experimental evidence suggests that certain class-A GPCRs form homo- and hetero-oligomers, in both transfected cells as well as extracted tissues. Symmetrical, parallel, dimeric interfaces have been observed in multiple crystal structures of class-A GPCRs, supporting the biological relevance of GPCR dimerization (<xref ref-type="bibr" rid="bib25">Huang et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Manglik et al., 2012</xref>; <xref ref-type="bibr" rid="bib26">Huang et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Yoshikawa et al., 2012</xref>; <xref ref-type="bibr" rid="bib32">Liu et al., 2012</xref>). However, non-symmetric dimerization is rarely seen in crystal structures of class-A GPCRs. A case similar to what we observed in DRD4 crystal is revealed in a previously reported complex structure of the α<sub>2A</sub> receptor crystallized with a high-affinity antagonist (<xref ref-type="bibr" rid="bib32">Liu et al., 2012</xref>). Nevertheless, in the α<sub>2A</sub> receptor case lipids and cholesterols were trapped in the interface groove, preventing any direct contact between the protomers. Moreover, our structural observations are in agreement with results from single-molecule dynamic studies showing that dimerization and/or oligomerization of GPCRs are more dynamic than previously believed (<xref ref-type="bibr" rid="bib48">Scarselli et al., 2016</xref>). More intriguingly, it had been reported that, when co-expressed, two different epitope-tagged D4 receptors can be co-immuno-precipitated, suggesting that multiple DRD4 molecules form dimeric/oligomeric complexes within the cell membrane (<xref ref-type="bibr" rid="bib41">Oak et al., 2000</xref>). The observed unusual non-symmetric dimerization in our crystal structure may suggest a mechanism of concentration-dependent regulation of the DRD4 activity in membrane, which deserves more rigorous in vivo verification in the future.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Gene (<italic>Mouse</italic>)</td><td>DRD4</td><td>SUNGENE BIOTECH</td><td>GenBank: BC051421.1</td><td/></tr><tr><td>Cell line (<italic>Spodoptera frugiperda</italic>)</td><td>Sf9 and High5</td><td>Thermo Fisher Scientific</td><td>Sf9: B825-01 <break/>High5:B85502</td><td/></tr><tr><td>Cell line (<italic>Homo sapiens</italic>)</td><td>HEK293t</td><td>ATCC</td><td>catalog numbers: CRL-3216</td><td/></tr><tr><td>Transfected construct (<italic>Spodoptera frugiperda</italic>)</td><td>pFastBac1-DRD4-BRIL</td><td>This paper</td><td/><td>Crystal construct</td></tr><tr><td>Transfected construct (<italic>Homo sapiens</italic>)</td><td>pcDNA3.1-DRD4-cpGFP</td><td>This paper</td><td/><td>Fluorescent sensor-based ligand-binding assay</td></tr><tr><td>Recombinant DNA reagent</td><td>pFastBac1</td><td>Thermo Fisher Scientific</td><td>catalog numbers: 10359016</td><td/></tr><tr><td>Recombinant DNA reagent</td><td>pcDNA3.1 <break/>(plasmid)</td><td>Thermo Fisher Scientific</td><td>catalog numbers: V79020</td><td>Mammalian expression vector</td></tr><tr><td>Commercial assay or kit</td><td>Bac-to-Bac Baculovirus Expression system</td><td>Thermo Fisher Scientific</td><td>Catalog number: 10359016</td><td/></tr><tr><td>Chemical compound, drug</td><td>L745870</td><td>Tocris</td><td>Catalog number: 158985-00-3</td><td/></tr><tr><td>Software, algorithm</td><td>XDS program package</td><td><xref ref-type="bibr" rid="bib30">Kabsch, 2010</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>PHENIX</td><td><xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref></td><td/><td/></tr><tr><td>Software, algorithm</td><td>Maestro</td><td>SCHRÖDINGER</td><td/><td/></tr><tr><td>Software, algorithm</td><td>Fiji</td><td><xref ref-type="bibr" rid="bib50">Schindelin et al., 2012</xref></td><td/><td/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Expression and purification of DRD4-BRIL</title><p>We generated a mouse DRD4 construct containing the A1–L106 region of the BRIL (with the point mutations M7W, H102I, and R106L) from <italic>Escherichia coli</italic> in the place of residues A220<sup>5.70</sup>–A302<sup>6.24</sup> of the receptor ICL3 (<xref ref-type="bibr" rid="bib16">Chun et al., 2012</xref>). This chimera construct of DRD4 was subcloned into a modified pFastBac1 vector (Thermo Fisher) that contained an expression cassette with a hemagglutinin (HA) signal sequence followed by a FLAG-tag at the N-terminus of the receptor sequence and a PreScission Protease (PPase) recognition site followed by EGFP (enhanced GFP) and a His<sub>10</sub>-tag at the C-terminus. The fusion protein was expressed using the Bac-to-Bac Baculovirus Expression System (Thermo Fisher) in High 5 strain of <italic>Spodoptera frugiperda</italic> cells for 48 hr. Harvested cells were then flash-frozen in liquid nitrogen and stored in –80°C until further use.</p><p>Cell membranes were obtained by Dounce homogenization using purification buffer A [25 mM HEPES (pH 7.4) and 150 mM NaCl]. Washed membranes were resuspended in buffer B [25 mM HEPES (pH 7.4), 150 mM NaCl, 30 µM L745870 (Tocris, Cat.# 158985-00-3), and 0.2% (w/v) iodoacetamide], with 80 mL buffer B per 0.4 L cultured biomass, and incubated at 4°C for 1 hr. The membrane was then solubilized by adding a detergent mixture [final 1% (w/v) n-dodecyl-β-D-maltopyranoside (DDM; Anatrace), and 0.15% (w/v) cholesteryl hemisuccinate (CHS; Sigma Aldrich)] for 1.5 hr at 4°C. The supernatant was isolated by centrifugation at 150,000 × <italic>g</italic> for 30 min. TALON IMAC resin (2 mL; Clontech) in 5 mM imidazole (pH 7.5) was added to the supernatant. The mixture was incubated at 4°C for 2–3 hr. The resin was transferred into a gravity column and washed with 15 column volumes of wash buffer C [25 mM HEPES (pH 7.4), 150 mM NaCl, 0.05% (w/v) DDM, 0.015% (w/v) CHS, 30 mM imidazole, and 30 µM L745870]. The resin-binding protein was then treated overnight with homemade His-tagged PPase in 10 mL buffer C. The flow through was then concentrated to 1 mL before being loaded onto a Superdex-200 column (GE healthcare). Fractions were collected from the monodispersed peak (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>) and pooled into one tube. L745870 (final concentration 50 µM) was added to the pooled protein sample and equilibrated for 1 hr before being concentrated to ~60 mg/mL with a 50 kDa cut-off centrifuge concentrator (Millipore).</p></sec><sec id="s4-2"><title>Lipidic cubic phase crystallization</title><p>The protein sample was reconstituted into LCP by mixing 40% sample with 60% lipid [10% (w/w) cholesterol, and 90% (w/w) monoolein] using the twin-syringe method (<xref ref-type="bibr" rid="bib9">Caffrey, 2009</xref>). The protein-lipid mixture was dispensed as 40 nL drops onto glass sandwich plates (Shanghai FAstal BioTechô Inc) using a hand-held dispenser (Art Robbins Instruments) and overlaid with 0.8 µL of precipitant solution. Protein crystals were obtained from precipitant solution containing 100 mM citrate acid/NaOH (pH 5.0–6.0), 0–150 mM salts, and 30% PEG550DME or PEG600 (<xref ref-type="fig" rid="fig1">Figure 1</xref>-figure Supplements 1c<sub>i-iv</sub>). The best crystals grew in 100 mM MES (pH 6.0), 50 mM ammonium citrate, and 30% PEG400 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1cv</xref>). Crystals grew to a full size of ~50 µm×20 µm×5 µm within one week, and were harvested directly from the LCP matrix using 50 µm micromounts (MiTeGen, Cat.# M2-L19-50), before flash-frozen in liquid nitrogen until further use.</p></sec><sec id="s4-3"><title>Data collection, structure solution and refinement</title><p>X-ray diffraction data were collected at the SPring-8 beamline 41XU, Hyogo, Japan, using an EIGER16M detector (Dectris; X-ray wavelength 1.0000 Å). A raster system was used to locate the best diffracting parts of single crystals (<xref ref-type="bibr" rid="bib12">Cherezov et al., 2009</xref>). The crystals were exposed to a 10 μm unattenuated mini-beam for 0.1 s and 0.2° oscillation per frame. Most crystals of the DRD4-L745870 complex diffracted to a resolution of 3.5–4.0 Å. The software package, XDS (<xref ref-type="bibr" rid="bib30">Kabsch, 2010</xref>), was used for integrating and scaling data from 28 best-diffracting crystals.</p><p>The DRD4-L74570 complex was solved by molecular replacement using the PHENIX program (<xref ref-type="bibr" rid="bib1">Adams et al., 2010</xref>; <xref ref-type="bibr" rid="bib20">Emsley et al., 2010</xref>) and two independent search models, namely, the receptor portion of human DRD4 (PDB ID: 5WIU) (<xref ref-type="bibr" rid="bib63">Wang et al., 2017</xref>) and the BRIL protein (PDB ID: 1M6T) (<xref ref-type="bibr" rid="bib15">Chu et al., 2002</xref>). Refinement was performed with PHENIX_REFINE, iterated with visual examination and rebuilding of the refined model using the program COOT (<xref ref-type="bibr" rid="bib20">Emsley et al., 2010</xref>) and |2F<sub>o</sub>|–|F<sub>c</sub>|, |F<sub>o</sub>|–|F<sub>c</sub>|, and omit maps. Simulation of ligand docking in receptor was done with Maestro (SCHRÖDINGER)(<xref ref-type="bibr" rid="bib22">Friesner et al., 2006</xref>).</p></sec><sec id="s4-4"><title>Fluorescent sensor-based ligand-binding assay</title><p>Sequences encoding a cleavable HA secretion-signaling motif and a FLAG epitope were placed at the 5’-end of the DRD4 constructs (WT* and ‘Crystal’ in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a</xref>). <italic>Sal</italic>I and <italic>Not</italic>I cleavage sites were created at the 5’- and 3’-ends, respectively, for cloning into pcDNA-3.1 (Thermo Fisher) to generate all mammalian cell-expression constructs.</p><p>Coupling between conformational changes and chromophore fluorescence were anticipated to follow the reported example of dLight1 (<xref ref-type="bibr" rid="bib44">Patriarchi et al., 2018</xref>) which is a DRD2 variant. In particular, the cpGFP module (LSSLE-cpGFP-LPDQL) was copied from the plasmid GCaMP6 (<xref ref-type="bibr" rid="bib11">Chen et al., 2013</xref>) and inserted into DRD4 variants of WT* and point mutations as well as the ‘crystallization’ construct to replace the segment of R217<sup>5.67</sup>–W306<sup>6.28</sup>.</p></sec><sec id="s4-5"><title>Cell culture, imaging, and quantification</title><p>HEK293T cells were cultured in glass-bottom cell-culture dish (NEST, Cat.# 801001) and transfected with DRD4-cpGFP expression plasmid using polyetherimide (Sigma Aldrich). Cell imaging was performed using a 60 × oil based objective on an inverted OLYMPUS FV1200 laser scanning confocal microscope with 488/513 nm ex/em wavelengths. For testing DRD4-cpGFP responses, different ligands were directly applied to the bath during the imaging session. Reproducible results were obtained after repeating all assays 2–3 times. Mean intensity of ROI (region of interested) in every frame was calculated using the Fiji software (<xref ref-type="bibr" rid="bib50">Schindelin et al., 2012</xref>). No commonly misidentified cell lines were used. The cell lines are negative for mycoplasma contamination.</p></sec><sec id="s4-6"><title>Protein cross-linking</title><p>Purified protein (1 mg/mL) was incubated with serial dilutions (0–5 mM) of glutaraldehyde dissolved in reaction buffer [25 mM HEPES (pH 7.4), 150 mM NaCl, 0.05% (w/v) DDM, and 0.015% (w/v) CHS] at room temperature for 1 hr. Cross-linking was stopped by adding in 5 × loading buffer [250 mM Tris-HCl (pH 6.8), 10% (w/v) SDS, 0.5% (w/v) bromophenol blue, 50% (v/v) glycerol, and 5% (w/v) β-Mercaptoethanol] before the sample was analyzed by SDS-PAGE.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors thank staffs of the Protein Science Core Facility of the Institute of Biophysics for their excellent assistance in protein characterization and thank Ms. Yan Teng of the Biological Imaging Core Facility for helping in confocal microscopy analysis. The synchrotron radiation experiments were performed at BL41XU of SPring-8 with approval from the Japan Synchrotron Radiation Research Institute (proposal number: 2018A2559). We thank the BL41XU beamline staff members for help with X-ray data collection. We thank Ms. Bei Yang for experimental assistance. We are particularly thankful to Dr. Yulong Li of the Peking University for the kind gift of the plasmid of the DRD2-cpGFP fusion construct. We also thank Dr. Torsten Juelich (Peking University, China) for linguistic assistance during the preparation of this manuscript. This work was supported by the CAS Strategic Priority Research Program (XDB08020301), the Ministry of Science and Technology (China) (2015CB910104), and the National Natural Science Foundation of China (31470745).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Validation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Data curation, Software, Methodology</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Supervision, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Data collection and refinement statistics for the mouse DRD4 and L745870 complex.</title><p><sup>a</sup>. Values in parentheses present the highest resolution shell. CC<sub>1/2</sub>** (<xref ref-type="bibr" rid="bib19">Diederichs and Karplus, 2013</xref>). <sup>b</sup>. All outliers are located in loops not involved in ligand binding.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-48822-supp1-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-48822-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Diffraction data have been deposited in PDB under the accession code 6IQL.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Can</surname><given-names>Cao</given-names></name><name><surname>Xuejun</surname><given-names>Cai Zhang</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Crystal structure of dopamine receptor D4 bound to the subtype-selective ligand, L745870</data-title><source>Protein Data Bank</source><pub-id assigning-authority="PDB" pub-id-type="accession" xlink:href="http://www.rcsb.org/structure/6IQL">6IQL</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>PD</given-names></name><name><surname>Afonine</surname> <given-names>PV</given-names></name><name><surname>Bunkóczi</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>VB</given-names></name><name><surname>Davis</surname> <given-names>IW</given-names></name><name><surname>Echols</surname> <given-names>N</given-names></name><name><surname>Headd</surname> <given-names>JJ</given-names></name><name><surname>Hung</surname> <given-names>LW</given-names></name><name><surname>Kapral</surname> <given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname> <given-names>RW</given-names></name><name><surname>McCoy</surname> <given-names>AJ</given-names></name><name><surname>Moriarty</surname> <given-names>NW</given-names></name><name><surname>Oeffner</surname> <given-names>R</given-names></name><name><surname>Read</surname> <given-names>RJ</given-names></name><name><surname>Richardson</surname> <given-names>DC</given-names></name><name><surname>Richardson</surname> <given-names>JS</given-names></name><name><surname>Terwilliger</surname> <given-names>TC</given-names></name><name><surname>Zwart</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title><italic>PHENIX</italic>: a comprehensive Python-based system for macromolecular structure solution</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>66</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname> <given-names>AI</given-names></name><name><surname>Mileni</surname> <given-names>M</given-names></name><name><surname>Chien</surname> <given-names>EY</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Microscale fluorescent thermal stability assay for membrane proteins</article-title><source>Structure</source><volume>16</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.str.2008.02.004</pub-id><pub-id pub-id-type="pmid">18334210</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballesteros</surname> <given-names>JA</given-names></name><name><surname>Weinstein</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein-coupled receptors</article-title><source>Methods in Neurosciences</source><volume>25</volume><fpage>366</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/S1043-9471(05)80049-7</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaulieu</surname> <given-names>JM</given-names></name><name><surname>Gainetdinov</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The physiology, signaling, and pharmacology of dopamine receptors</article-title><source>Pharmacological Reviews</source><volume>63</volume><fpage>182</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1124/pr.110.002642</pub-id><pub-id pub-id-type="pmid">21303898</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belliotti</surname> <given-names>TR</given-names></name><name><surname>Brink</surname> <given-names>WA</given-names></name><name><surname>Kesten</surname> <given-names>SR</given-names></name><name><surname>Rubin</surname> <given-names>JR</given-names></name><name><surname>Wustrow</surname> <given-names>DJ</given-names></name><name><surname>Zoski</surname> <given-names>KT</given-names></name><name><surname>Whetzel</surname> <given-names>SZ</given-names></name><name><surname>Corbin</surname> <given-names>AE</given-names></name><name><surname>Pugsley</surname> <given-names>TA</given-names></name><name><surname>Heffner</surname> <given-names>TG</given-names></name><name><surname>Wise</surname> <given-names>LD</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Isoindolinone enantiomers having affinity for the dopamine D4 receptor</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>8</volume><fpage>1499</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1016/S0960-894X(98)00252-2</pub-id><pub-id pub-id-type="pmid">9873377</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boeckler</surname> <given-names>F</given-names></name><name><surname>Russig</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Löber</surname> <given-names>S</given-names></name><name><surname>Schetz</surname> <given-names>J</given-names></name><name><surname>Hübner</surname> <given-names>H</given-names></name><name><surname>Ferger</surname> <given-names>B</given-names></name><name><surname>Gmeiner</surname> <given-names>P</given-names></name><name><surname>Feldon</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia</article-title><source>Psychopharmacology</source><volume>175</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s00213-004-1782-1</pub-id><pub-id pub-id-type="pmid">15007532</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brioni</surname> <given-names>JD</given-names></name><name><surname>Moreland</surname> <given-names>RB</given-names></name><name><surname>Cowart</surname> <given-names>M</given-names></name><name><surname>Hsieh</surname> <given-names>GC</given-names></name><name><surname>Stewart</surname> <given-names>AO</given-names></name><name><surname>Hedlund</surname> <given-names>P</given-names></name><name><surname>Donnelly-Roberts</surname> <given-names>DL</given-names></name><name><surname>Nakane</surname> <given-names>M</given-names></name><name><surname>Lynch</surname> <given-names>JJ</given-names></name><name><surname>Kolasa</surname> <given-names>T</given-names></name><name><surname>Polakowski</surname> <given-names>JS</given-names></name><name><surname>Osinski</surname> <given-names>MA</given-names></name><name><surname>Marsh</surname> <given-names>K</given-names></name><name><surname>Andersson</surname> <given-names>KE</given-names></name><name><surname>Sullivan</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats </article-title><source>PNAS</source><volume>101</volume><fpage>6758</fpage><lpage>6763</lpage><pub-id pub-id-type="doi">10.1073/pnas.0308292101</pub-id><pub-id pub-id-type="pmid">15087502</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname> <given-names>LJ</given-names></name><name><surname>Collinson</surname> <given-names>N</given-names></name><name><surname>Cook</surname> <given-names>GP</given-names></name><name><surname>Curtis</surname> <given-names>N</given-names></name><name><surname>Freedman</surname> <given-names>SB</given-names></name><name><surname>Kulagowski</surname> <given-names>JJ</given-names></name><name><surname>Leeson</surname> <given-names>PD</given-names></name><name><surname>Patel</surname> <given-names>S</given-names></name><name><surname>Ragan</surname> <given-names>CI</given-names></name><name><surname>Ridgill</surname> <given-names>M</given-names></name><name><surname>Saywell</surname> <given-names>KL</given-names></name><name><surname>Tricklebank</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>283</volume><fpage>1256</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">9400001</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caffrey</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crystallizing membrane proteins for structure determination: use of lipidic mesophases</article-title><source>Annual Review of Biophysics</source><volume>38</volume><fpage>29</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1146/annurev.biophys.050708.133655</pub-id><pub-id pub-id-type="pmid">19086821</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname> <given-names>C</given-names></name><name><surname>Tan</surname> <given-names>Q</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>He</surname> <given-names>L</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Qiao</surname> <given-names>A</given-names></name><name><surname>Lu</surname> <given-names>M</given-names></name><name><surname>Yi</surname> <given-names>C</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Rao</surname> <given-names>Z</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Zhao</surname> <given-names>Y</given-names></name><name><surname>Liu</surname> <given-names>J</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>XC</given-names></name><name><surname>Wu</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural basis for signal recognition and transduction by platelet-activating-factor receptor</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>25</volume><fpage>488</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/s41594-018-0068-y</pub-id><pub-id pub-id-type="pmid">29808000</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>TW</given-names></name><name><surname>Wardill</surname> <given-names>TJ</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Pulver</surname> <given-names>SR</given-names></name><name><surname>Renninger</surname> <given-names>SL</given-names></name><name><surname>Baohan</surname> <given-names>A</given-names></name><name><surname>Schreiter</surname> <given-names>ER</given-names></name><name><surname>Kerr</surname> <given-names>RA</given-names></name><name><surname>Orger</surname> <given-names>MB</given-names></name><name><surname>Jayaraman</surname> <given-names>V</given-names></name><name><surname>Looger</surname> <given-names>LL</given-names></name><name><surname>Svoboda</surname> <given-names>K</given-names></name><name><surname>Kim</surname> <given-names>DS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ultrasensitive fluorescent proteins for imaging neuronal activity</article-title><source>Nature</source><volume>499</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/nature12354</pub-id><pub-id pub-id-type="pmid">23868258</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Griffith</surname> <given-names>MT</given-names></name><name><surname>Hilgart</surname> <given-names>MC</given-names></name><name><surname>Sanishvili</surname> <given-names>R</given-names></name><name><surname>Nagarajan</surname> <given-names>V</given-names></name><name><surname>Stepanov</surname> <given-names>S</given-names></name><name><surname>Fischetti</surname> <given-names>RF</given-names></name><name><surname>Kuhn</surname> <given-names>P</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 µm size X-ray synchrotron beam</article-title><source>Journal of the Royal Society Interface</source><volume>6</volume><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1098/rsif.2009.0142.focus</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname> <given-names>EY</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Shi</surname> <given-names>L</given-names></name><name><surname>Newman</surname> <given-names>AH</given-names></name><name><surname>Javitch</surname> <given-names>JA</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</article-title><source>Science</source><volume>330</volume><fpage>1091</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1126/science.1197410</pub-id><pub-id pub-id-type="pmid">21097933</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>S</given-names></name><name><surname>Haggart</surname> <given-names>D</given-names></name><name><surname>Toll</surname> <given-names>L</given-names></name><name><surname>Cuny</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Synthesis, receptor binding and functional studies of mesoridazine stereoisomers</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>14</volume><fpage>4379</fpage><lpage>4382</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2004.06.078</pub-id><pub-id pub-id-type="pmid">15357957</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname> <given-names>R</given-names></name><name><surname>Takei</surname> <given-names>J</given-names></name><name><surname>Knowlton</surname> <given-names>JR</given-names></name><name><surname>Andrykovitch</surname> <given-names>M</given-names></name><name><surname>Pei</surname> <given-names>W</given-names></name><name><surname>Kajava</surname> <given-names>AV</given-names></name><name><surname>Steinbach</surname> <given-names>PJ</given-names></name><name><surname>Ji</surname> <given-names>X</given-names></name><name><surname>Bai</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Redesign of a four-helix bundle protein by phage display coupled with proteolysis and structural characterization by NMR and X-ray crystallography</article-title><source>Journal of Molecular Biology</source><volume>323</volume><fpage>253</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(02)00884-7</pub-id><pub-id pub-id-type="pmid">12381319</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname> <given-names>E</given-names></name><name><surname>Thompson</surname> <given-names>AA</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Roth</surname> <given-names>CB</given-names></name><name><surname>Griffith</surname> <given-names>MT</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Kunken</surname> <given-names>J</given-names></name><name><surname>Xu</surname> <given-names>F</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors</article-title><source>Structure</source><volume>20</volume><fpage>967</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1016/j.str.2012.04.010</pub-id><pub-id pub-id-type="pmid">22681902</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname> <given-names>KY</given-names></name><name><surname>Rasmussen</surname> <given-names>SG</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>DeVree</surname> <given-names>BT</given-names></name><name><surname>Chae</surname> <given-names>PS</given-names></name><name><surname>Calinski</surname> <given-names>D</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Woods</surname> <given-names>VL</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Conformational changes in the G protein gs induced by the β2 adrenergic receptor</article-title><source>Nature</source><volume>477</volume><fpage>611</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/nature10488</pub-id><pub-id pub-id-type="pmid">21956331</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>BA</given-names></name><name><surname>Henningsen</surname> <given-names>RA</given-names></name><name><surname>Spanoyannis</surname> <given-names>A</given-names></name><name><surname>Neve</surname> <given-names>RL</given-names></name><name><surname>Neve</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors</article-title><source>Journal of Neurochemistry</source><volume>59</volume><fpage>627</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1992.tb09416.x</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diederichs</surname> <given-names>K</given-names></name><name><surname>Karplus</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Better models by discarding data?</article-title><source>Acta Crystallographica Section D Biological Crystallography</source><volume>69</volume><fpage>1215</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1107/S0907444913001121</pub-id><pub-id pub-id-type="pmid">23793147</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>P</given-names></name><name><surname>Lohkamp</surname> <given-names>B</given-names></name><name><surname>Scott</surname> <given-names>WG</given-names></name><name><surname>Cowtan</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Features and development of <italic>coot</italic></article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farran</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An update on the physiological and therapeutic relevance of GPCR oligomers</article-title><source>Pharmacological Research</source><volume>117</volume><fpage>303</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2017.01.008</pub-id><pub-id pub-id-type="pmid">28087443</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friesner</surname> <given-names>RA</given-names></name><name><surname>Murphy</surname> <given-names>RB</given-names></name><name><surname>Repasky</surname> <given-names>MP</given-names></name><name><surname>Frye</surname> <given-names>LL</given-names></name><name><surname>Greenwood</surname> <given-names>JR</given-names></name><name><surname>Halgren</surname> <given-names>TA</given-names></name><name><surname>Sanschagrin</surname> <given-names>PC</given-names></name><name><surname>Mainz</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes</article-title><source>Journal of Medicinal Chemistry</source><volume>49</volume><fpage>6177</fpage><lpage>6196</lpage><pub-id pub-id-type="doi">10.1021/jm051256o</pub-id><pub-id pub-id-type="pmid">17034125</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girault</surname> <given-names>JA</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The neurobiology of dopamine signaling</article-title><source>Archives of Neurology</source><volume>61</volume><fpage>641</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1001/archneur.61.5.641</pub-id><pub-id pub-id-type="pmid">15148138</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidaka</surname> <given-names>K</given-names></name><name><surname>Matsumoto</surname> <given-names>M</given-names></name><name><surname>Tada</surname> <given-names>S</given-names></name><name><surname>Tasaki</surname> <given-names>Y</given-names></name><name><surname>Yamaguchi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors</article-title><source>Neuroscience Letters</source><volume>186</volume><fpage>145</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(95)11306-H</pub-id><pub-id pub-id-type="pmid">7777184</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>JJ</given-names></name><name><surname>Huang</surname> <given-names>XY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Crystal structure of oligomeric β1-adrenergic G protein-coupled receptors in ligand-free basal state</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>20</volume><fpage>419</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2504</pub-id><pub-id pub-id-type="pmid">23435379</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>W</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Laeremans</surname> <given-names>T</given-names></name><name><surname>Feinberg</surname> <given-names>EN</given-names></name><name><surname>Sanborn</surname> <given-names>AL</given-names></name><name><surname>Kato</surname> <given-names>HE</given-names></name><name><surname>Livingston</surname> <given-names>KE</given-names></name><name><surname>Thorsen</surname> <given-names>TS</given-names></name><name><surname>Kling</surname> <given-names>RC</given-names></name><name><surname>Granier</surname> <given-names>S</given-names></name><name><surname>Gmeiner</surname> <given-names>P</given-names></name><name><surname>Husbands</surname> <given-names>SM</given-names></name><name><surname>Traynor</surname> <given-names>JR</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Steyaert</surname> <given-names>J</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural insights into µ-opioid receptor activation</article-title><source>Nature</source><volume>524</volume><fpage>315</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1038/nature14886</pub-id><pub-id pub-id-type="pmid">26245379</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulme</surname> <given-names>EC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>GPCR activation: a mutagenic spotlight on crystal structures</article-title><source>Trends in Pharmacological Sciences</source><volume>34</volume><fpage>67</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2012.11.002</pub-id><pub-id pub-id-type="pmid">23245528</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname> <given-names>PA</given-names></name><name><surname>Niemegeers</surname> <given-names>CJ</given-names></name><name><surname>Awouters</surname> <given-names>F</given-names></name><name><surname>Schellekens</surname> <given-names>KH</given-names></name><name><surname>Megens</surname> <given-names>AA</given-names></name><name><surname>Meert</surname> <given-names>TF</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>244</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="pmid">2450200</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Effects of dopamine D2-Like receptor antagonists on light responses of ganglion cells in Wild-Type and P23H rat retinas</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0146154</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0146154</pub-id><pub-id pub-id-type="pmid">26717015</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortagere</surname> <given-names>S</given-names></name><name><surname>Gmeiner</surname> <given-names>P</given-names></name><name><surname>Weinstein</surname> <given-names>H</given-names></name><name><surname>Schetz</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain</article-title><source>Molecular Pharmacology</source><volume>66</volume><fpage>1491</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1124/mol.104.001321</pub-id><pub-id pub-id-type="pmid">15448188</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Chun</surname> <given-names>E</given-names></name><name><surname>Thompson</surname> <given-names>AA</given-names></name><name><surname>Chubukov</surname> <given-names>P</given-names></name><name><surname>Xu</surname> <given-names>F</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Roth</surname> <given-names>CB</given-names></name><name><surname>Heitman</surname> <given-names>LH</given-names></name><name><surname>IJzerman</surname> <given-names>AP</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural basis for allosteric regulation of GPCRs by sodium ions</article-title><source>Science</source><volume>337</volume><fpage>232</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1126/science.1219218</pub-id><pub-id pub-id-type="pmid">22798613</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Gati</surname> <given-names>C</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>James</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>D</given-names></name><name><surname>Nelson</surname> <given-names>G</given-names></name><name><surname>Weierstall</surname> <given-names>U</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Barty</surname> <given-names>A</given-names></name><name><surname>Zatsepin</surname> <given-names>NA</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Messerschmidt</surname> <given-names>M</given-names></name><name><surname>Boutet</surname> <given-names>S</given-names></name><name><surname>Williams</surname> <given-names>GJ</given-names></name><name><surname>Koglin</surname> <given-names>JE</given-names></name><name><surname>Seibert</surname> <given-names>MM</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Shah</surname> <given-names>ST</given-names></name><name><surname>Basu</surname> <given-names>S</given-names></name><name><surname>Fromme</surname> <given-names>R</given-names></name><name><surname>Kupitz</surname> <given-names>C</given-names></name><name><surname>Rendek</surname> <given-names>KN</given-names></name><name><surname>Grotjohann</surname> <given-names>I</given-names></name><name><surname>Fromme</surname> <given-names>P</given-names></name><name><surname>Kirian</surname> <given-names>RA</given-names></name><name><surname>Beyerlein</surname> <given-names>KR</given-names></name><name><surname>White</surname> <given-names>TA</given-names></name><name><surname>Chapman</surname> <given-names>HN</given-names></name><name><surname>Caffrey</surname> <given-names>M</given-names></name><name><surname>Spence</surname> <given-names>JC</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Serial femtosecond crystallography of G protein-coupled receptors</article-title><source>Science</source><volume>342</volume><fpage>1521</fpage><lpage>1524</lpage><pub-id pub-id-type="doi">10.1126/science.1244142</pub-id><pub-id pub-id-type="pmid">24357322</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Kruse</surname> <given-names>AC</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Thian</surname> <given-names>FS</given-names></name><name><surname>Mathiesen</surname> <given-names>JM</given-names></name><name><surname>Sunahara</surname> <given-names>RK</given-names></name><name><surname>Pardo</surname> <given-names>L</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Granier</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Crystal structure of the µ-opioid receptor bound to a morphinan antagonist</article-title><source>Nature</source><volume>485</volume><fpage>321</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/nature10954</pub-id><pub-id pub-id-type="pmid">22437502</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michino</surname> <given-names>M</given-names></name><name><surname>Beuming</surname> <given-names>T</given-names></name><name><surname>Donthamsetti</surname> <given-names>P</given-names></name><name><surname>Newman</surname> <given-names>AH</given-names></name><name><surname>Javitch</surname> <given-names>JA</given-names></name><name><surname>Shi</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>What can crystal structures of aminergic receptors tell us about designing subtype-selective ligands?</article-title><source>Pharmacological Reviews</source><volume>67</volume><fpage>198</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1124/pr.114.009944</pub-id><pub-id pub-id-type="pmid">25527701</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millan</surname> <given-names>MJ</given-names></name><name><surname>Maiofiss</surname> <given-names>L</given-names></name><name><surname>Cussac</surname> <given-names>D</given-names></name><name><surname>Audinot</surname> <given-names>V</given-names></name><name><surname>Boutin</surname> <given-names>JA</given-names></name><name><surname>Newman-Tancredi</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes</article-title><source>Journal of Pharmacology and Experimental Therapeutics</source><volume>303</volume><fpage>791</fpage><lpage>804</lpage><pub-id pub-id-type="doi">10.1124/jpet.102.039867</pub-id><pub-id pub-id-type="pmid">12388666</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller-Gallacher</surname> <given-names>JL</given-names></name><name><surname>Nehmé</surname> <given-names>R</given-names></name><name><surname>Warne</surname> <given-names>T</given-names></name><name><surname>Edwards</surname> <given-names>PC</given-names></name><name><surname>Schertler</surname> <given-names>GF</given-names></name><name><surname>Leslie</surname> <given-names>AG</given-names></name><name><surname>Tate</surname> <given-names>CG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The 2.1 Å resolution structure of cyanopindolol-bound β1-adrenoceptor identifies an intramembrane na+ ion that stabilises the ligand-free receptor</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e92727</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092727</pub-id><pub-id pub-id-type="pmid">24663151</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname> <given-names>AM</given-names></name><name><surname>Hyde</surname> <given-names>TM</given-names></name><name><surname>Knable</surname> <given-names>MB</given-names></name><name><surname>Herman</surname> <given-names>MM</given-names></name><name><surname>Bigelow</surname> <given-names>LB</given-names></name><name><surname>Carter</surname> <given-names>JM</given-names></name><name><surname>Weinberger</surname> <given-names>DR</given-names></name><name><surname>Kleinman</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia</article-title><source>The Journal of Neuroscience</source><volume>15</volume><fpage>2186</fpage><lpage>2191</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.15-03-02186.1995</pub-id><pub-id pub-id-type="pmid">7891160</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neve</surname> <given-names>KA</given-names></name><name><surname>Seamans</surname> <given-names>JK</given-names></name><name><surname>Trantham-Davidson</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Dopamine receptor signaling</article-title><source>Journal of Receptors and Signal Transduction</source><volume>24</volume><fpage>165</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1081/RRS-200029981</pub-id><pub-id pub-id-type="pmid">15521361</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman-Tancredi</surname> <given-names>A</given-names></name><name><surname>Audinot-Bouchez</surname> <given-names>V</given-names></name><name><surname>Gobert</surname> <given-names>A</given-names></name><name><surname>Millan</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors</article-title><source>European Journal of Pharmacology</source><volume>319</volume><fpage>379</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(96)00985-5</pub-id><pub-id pub-id-type="pmid">9042615</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oak</surname> <given-names>JN</given-names></name><name><surname>Oldenhof</surname> <given-names>J</given-names></name><name><surname>Van Tol</surname> <given-names>HH</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The dopamine D(4) receptor: one decade of research</article-title><source>European Journal of Pharmacology</source><volume>405</volume><fpage>303</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(00)00562-8</pub-id><pub-id pub-id-type="pmid">11033337</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opazo</surname> <given-names>JC</given-names></name><name><surname>Zavala</surname> <given-names>K</given-names></name><name><surname>Miranda-Rottmann</surname> <given-names>S</given-names></name><name><surname>Araya</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evolution of dopamine receptors: phylogenetic evidence suggests a later origin of the DRD<sub>2l</sub> and DRD<sub>4rs</sub> dopamine receptor gene lineages</article-title><source>PeerJ</source><volume>6</volume><elocation-id>e4593</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.4593</pub-id><pub-id pub-id-type="pmid">29666757</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>S</given-names></name><name><surname>Freedman</surname> <given-names>S</given-names></name><name><surname>Chapman</surname> <given-names>KL</given-names></name><name><surname>Emms</surname> <given-names>F</given-names></name><name><surname>Fletcher</surname> <given-names>AE</given-names></name><name><surname>Knowles</surname> <given-names>M</given-names></name><name><surname>Marwood</surname> <given-names>R</given-names></name><name><surname>Mcallister</surname> <given-names>G</given-names></name><name><surname>Myers</surname> <given-names>J</given-names></name><name><surname>Curtis</surname> <given-names>N</given-names></name><name><surname>Kulagowski</surname> <given-names>JJ</given-names></name><name><surname>Leeson</surname> <given-names>PD</given-names></name><name><surname>Ridgill</surname> <given-names>M</given-names></name><name><surname>Graham</surname> <given-names>M</given-names></name><name><surname>Matheson</surname> <given-names>S</given-names></name><name><surname>Rathbone</surname> <given-names>D</given-names></name><name><surname>Watt</surname> <given-names>AP</given-names></name><name><surname>Bristow</surname> <given-names>LJ</given-names></name><name><surname>Rupniak</surname> <given-names>NM</given-names></name><name><surname>Baskin</surname> <given-names>E</given-names></name><name><surname>Lynch</surname> <given-names>JJ</given-names></name><name><surname>Ragan</surname> <given-names>CI</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>283</volume><fpage>636</fpage><lpage>647</lpage><pub-id pub-id-type="pmid">9353380</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patriarchi</surname> <given-names>T</given-names></name><name><surname>Cho</surname> <given-names>JR</given-names></name><name><surname>Merten</surname> <given-names>K</given-names></name><name><surname>Howe</surname> <given-names>MW</given-names></name><name><surname>Marley</surname> <given-names>A</given-names></name><name><surname>Xiong</surname> <given-names>WH</given-names></name><name><surname>Folk</surname> <given-names>RW</given-names></name><name><surname>Broussard</surname> <given-names>GJ</given-names></name><name><surname>Liang</surname> <given-names>R</given-names></name><name><surname>Jang</surname> <given-names>MJ</given-names></name><name><surname>Zhong</surname> <given-names>H</given-names></name><name><surname>Dombeck</surname> <given-names>D</given-names></name><name><surname>von Zastrow</surname> <given-names>M</given-names></name><name><surname>Nimmerjahn</surname> <given-names>A</given-names></name><name><surname>Gradinaru</surname> <given-names>V</given-names></name><name><surname>Williams</surname> <given-names>JT</given-names></name><name><surname>Tian</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ultrafast neuronal imaging of dopamine dynamics with designed genetically encoded sensors</article-title><source>Science</source><volume>360</volume><elocation-id>eaat4422</elocation-id><pub-id pub-id-type="doi">10.1126/science.aat4422</pub-id><pub-id pub-id-type="pmid">29853555</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname> <given-names>AM</given-names></name><name><surname>Manglik</surname> <given-names>A</given-names></name><name><surname>Kruse</surname> <given-names>AC</given-names></name><name><surname>Enos</surname> <given-names>MD</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Garcia</surname> <given-names>KC</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody</article-title><source>Nature</source><volume>502</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1038/nature12572</pub-id><pub-id pub-id-type="pmid">24056936</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rondou</surname> <given-names>P</given-names></name><name><surname>Haegeman</surname> <given-names>G</given-names></name><name><surname>Van Craenenbroeck</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The dopamine D4 receptor: biochemical and signalling properties</article-title><source>Cellular and Molecular Life Sciences</source><volume>67</volume><fpage>1971</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1007/s00018-010-0293-y</pub-id><pub-id pub-id-type="pmid">20165900</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname> <given-names>CB</given-names></name><name><surname>Hanson</surname> <given-names>MA</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Stabilization of the human beta2-adrenergic receptor TM4-TM3-TM5 Helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure</article-title><source>Journal of Molecular Biology</source><volume>376</volume><fpage>1305</fpage><lpage>1319</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.12.028</pub-id><pub-id pub-id-type="pmid">18222471</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarselli</surname> <given-names>M</given-names></name><name><surname>Annibale</surname> <given-names>P</given-names></name><name><surname>McCormick</surname> <given-names>PJ</given-names></name><name><surname>Kolachalam</surname> <given-names>S</given-names></name><name><surname>Aringhieri</surname> <given-names>S</given-names></name><name><surname>Radenovic</surname> <given-names>A</given-names></name><name><surname>Corsini</surname> <given-names>GU</given-names></name><name><surname>Maggio</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Revealing G-protein-coupled receptor oligomerization at the single-molecule level through a nanoscopic Lens: methods, dynamics and biological function</article-title><source>The FEBS Journal</source><volume>283</volume><fpage>1197</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1111/febs.13577</pub-id><pub-id pub-id-type="pmid">26509747</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schetz</surname> <given-names>JA</given-names></name><name><surname>Benjamin</surname> <given-names>PS</given-names></name><name><surname>Sibley</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Nonconserved residues in the second transmembrane-spanning domain of the D-4 dopamine receptor are molecular determinants of D-4-selective pharmacology</article-title><source>Molecular Pharmacology</source><volume>57</volume><fpage>144</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">10617689</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname> <given-names>J</given-names></name><name><surname>Arganda-Carreras</surname> <given-names>I</given-names></name><name><surname>Frise</surname> <given-names>E</given-names></name><name><surname>Kaynig</surname> <given-names>V</given-names></name><name><surname>Longair</surname> <given-names>M</given-names></name><name><surname>Pietzsch</surname> <given-names>T</given-names></name><name><surname>Preibisch</surname> <given-names>S</given-names></name><name><surname>Rueden</surname> <given-names>C</given-names></name><name><surname>Saalfeld</surname> <given-names>S</given-names></name><name><surname>Schmid</surname> <given-names>B</given-names></name><name><surname>Tinevez</surname> <given-names>JY</given-names></name><name><surname>White</surname> <given-names>DJ</given-names></name><name><surname>Hartenstein</surname> <given-names>V</given-names></name><name><surname>Eliceiri</surname> <given-names>K</given-names></name><name><surname>Tomancak</surname> <given-names>P</given-names></name><name><surname>Cardona</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeman</surname> <given-names>P</given-names></name><name><surname>Guan</surname> <given-names>HC</given-names></name><name><surname>Van Tol</surname> <given-names>HH</given-names></name><name><surname>Niznik</surname> <given-names>HB</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Low <italic>density of dopamine D4 receptors in Parkinson's, schizophrenia,</italic> and control brain striata</article-title><source>Synapse</source><volume>14</volume><fpage>247</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1002/syn.890140402</pub-id><pub-id pub-id-type="pmid">8248849</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeman</surname> <given-names>P</given-names></name><name><surname>Lee</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1975">1975</year><article-title>Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons</article-title><source>Science</source><volume>188</volume><fpage>1217</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1126/science.1145194</pub-id><pub-id pub-id-type="pmid">1145194</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname> <given-names>YH</given-names></name><name><surname>Chung</surname> <given-names>FZ</given-names></name><name><surname>Pugsley</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cloning, expression and characterization of a human dopamine D4.2 receptor (CHO K1 cells) and various D4.2/D2L chimeras (COS-7 cells)</article-title><source>Progress in Neuro-Psychopharmacology and Biological Psychiatry</source><volume>21</volume><fpage>153</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/S0278-5846(96)00168-6</pub-id><pub-id pub-id-type="pmid">9075264</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimamura</surname> <given-names>T</given-names></name><name><surname>Shiroishi</surname> <given-names>M</given-names></name><name><surname>Weyand</surname> <given-names>S</given-names></name><name><surname>Tsujimoto</surname> <given-names>H</given-names></name><name><surname>Winter</surname> <given-names>G</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Abagyan</surname> <given-names>R</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Iwata</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Structure of the human histamine H1 receptor complex with doxepin</article-title><source>Nature</source><volume>475</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nature10236</pub-id><pub-id pub-id-type="pmid">21697825</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname> <given-names>MM</given-names></name><name><surname>Ballesteros</surname> <given-names>JA</given-names></name><name><surname>Chiappa</surname> <given-names>V</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Suehiro</surname> <given-names>M</given-names></name><name><surname>Hartman</surname> <given-names>DS</given-names></name><name><surname>Godel</surname> <given-names>T</given-names></name><name><surname>Snyder</surname> <given-names>LA</given-names></name><name><surname>Sakmar</surname> <given-names>TP</given-names></name><name><surname>Javitch</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments</article-title><source>Molecular Pharmacology</source><volume>56</volume><fpage>1116</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1124/mol.56.6.1116</pub-id><pub-id pub-id-type="pmid">10570038</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokoloff</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The role of the brain-derived neurotrophic factor/dopamine D3 receptor pathway in the responses to drugs and drug-associated stimuli</article-title><source>Neuropsychopharmacology</source><volume>31</volume><fpage>S3</fpage><lpage>S4</lpage></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strader</surname> <given-names>CD</given-names></name><name><surname>Candelore</surname> <given-names>MR</given-names></name><name><surname>Hill</surname> <given-names>WS</given-names></name><name><surname>Sigal</surname> <given-names>IS</given-names></name><name><surname>Dixon</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor</article-title><source>The Journal of Biological Chemistry</source><volume>264</volume><fpage>13572</fpage><lpage>13578</lpage><pub-id pub-id-type="pmid">2547766</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname> <given-names>F</given-names></name><name><surname>Zeng</surname> <given-names>J</given-names></name><name><surname>Jing</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>J</given-names></name><name><surname>Feng</surname> <given-names>J</given-names></name><name><surname>Owen</surname> <given-names>SF</given-names></name><name><surname>Luo</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Yamaguchi</surname> <given-names>T</given-names></name><name><surname>Yong</surname> <given-names>Z</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Peng</surname> <given-names>W</given-names></name><name><surname>Wang</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Du</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>D</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Kreitzer</surname> <given-names>AC</given-names></name><name><surname>Cui</surname> <given-names>G</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A genetically encoded fluorescent sensor enables rapid and specific detection of dopamine in flies, fish, and mice</article-title><source>Cell</source><volume>174</volume><fpage>481</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.06.042</pub-id><pub-id pub-id-type="pmid">30007419</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thal</surname> <given-names>DM</given-names></name><name><surname>Sun</surname> <given-names>B</given-names></name><name><surname>Feng</surname> <given-names>D</given-names></name><name><surname>Nawaratne</surname> <given-names>V</given-names></name><name><surname>Leach</surname> <given-names>K</given-names></name><name><surname>Felder</surname> <given-names>CC</given-names></name><name><surname>Bures</surname> <given-names>MG</given-names></name><name><surname>Evans</surname> <given-names>DA</given-names></name><name><surname>Weis</surname> <given-names>WI</given-names></name><name><surname>Bachhawat</surname> <given-names>P</given-names></name><name><surname>Kobilka</surname> <given-names>TS</given-names></name><name><surname>Sexton</surname> <given-names>PM</given-names></name><name><surname>Kobilka</surname> <given-names>BK</given-names></name><name><surname>Christopoulos</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Crystal structures of the M1 and M4 muscarinic acetylcholine receptors</article-title><source>Nature</source><volume>531</volume><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1038/nature17188</pub-id><pub-id pub-id-type="pmid">26958838</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truffinet</surname> <given-names>P</given-names></name><name><surname>Tamminga</surname> <given-names>CA</given-names></name><name><surname>Fabre</surname> <given-names>LF</given-names></name><name><surname>Meltzer</surname> <given-names>HY</given-names></name><name><surname>Rivière</surname> <given-names>ME</given-names></name><name><surname>Papillon-Downey</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Placebo-controlled study of the D4/5-HT2A antagonist fananserin in the treatment of schizophrenia</article-title><source>The American Journal of Psychiatry</source><volume>156</volume><fpage>419</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1176/ajp.156.3.419</pub-id><pub-id pub-id-type="pmid">10080558</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rhee</surname> <given-names>AM</given-names></name><name><surname>Jacobson</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Molecular architecture of G Protein-Coupled receptors</article-title><source>Drug Development Research</source><volume>37</volume><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2299(199601)37:1&lt;1::AID-DDR1&gt;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">21921973</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Ma</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Katritch</surname> <given-names>V</given-names></name><name><surname>Han</surname> <given-names>GW</given-names></name><name><surname>Liu</surname> <given-names>W</given-names></name><name><surname>Huang</surname> <given-names>XP</given-names></name><name><surname>Vardy</surname> <given-names>E</given-names></name><name><surname>McCorvy</surname> <given-names>JD</given-names></name><name><surname>Gao</surname> <given-names>X</given-names></name><name><surname>Zhou</surname> <given-names>XE</given-names></name><name><surname>Melcher</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Bai</surname> <given-names>F</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>L</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name><name><surname>Cherezov</surname> <given-names>V</given-names></name><name><surname>Stevens</surname> <given-names>RC</given-names></name><name><surname>Xu</surname> <given-names>HE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural basis for molecular recognition at serotonin receptors</article-title><source>Science</source><volume>340</volume><fpage>610</fpage><lpage>614</lpage><pub-id pub-id-type="doi">10.1126/science.1232807</pub-id><pub-id pub-id-type="pmid">23519210</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Levit</surname> <given-names>A</given-names></name><name><surname>Che</surname> <given-names>T</given-names></name><name><surname>Betz</surname> <given-names>RM</given-names></name><name><surname>McCorvy</surname> <given-names>JD</given-names></name><name><surname>Venkatakrishnan</surname> <given-names>AJ</given-names></name><name><surname>Huang</surname> <given-names>XP</given-names></name><name><surname>Dror</surname> <given-names>RO</given-names></name><name><surname>Shoichet</surname> <given-names>BK</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>D<sub>4</sub> dopamine receptor high-resolution structures enable the discovery of selective agonists</article-title><source>Science</source><volume>358</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1126/science.aan5468</pub-id><pub-id pub-id-type="pmid">29051383</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Che</surname> <given-names>T</given-names></name><name><surname>Levit</surname> <given-names>A</given-names></name><name><surname>Shoichet</surname> <given-names>BK</given-names></name><name><surname>Wacker</surname> <given-names>D</given-names></name><name><surname>Roth</surname> <given-names>BL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone</article-title><source>Nature</source><volume>555</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1038/nature25758</pub-id><pub-id pub-id-type="pmid">29466326</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname> <given-names>JM</given-names></name><name><surname>Sanyal</surname> <given-names>S</given-names></name><name><surname>Van Tol</surname> <given-names>HH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Dopamine D2 and D4 receptor ligands: relation to antipsychotic action</article-title><source>European Journal of Pharmacology</source><volume>351</volume><fpage>273</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(98)00312-4</pub-id><pub-id pub-id-type="pmid">9721018</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname> <given-names>Y</given-names></name><name><surname>Kobayashi</surname> <given-names>K</given-names></name><name><surname>Oishi</surname> <given-names>S</given-names></name><name><surname>Fujii</surname> <given-names>N</given-names></name><name><surname>Furuya</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>22</volume><fpage>2146</fpage><lpage>2150</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.01.134</pub-id><pub-id pub-id-type="pmid">22365757</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48822.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Liu</surname><given-names>Zhi-Jie</given-names> </name><role>Reviewer</role><aff><institution>Kunming Medical University</institution><country>China</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This manuscript described the crystal structure of mouse dopamine D4 in complex with a selective antagonist L745870. The structure, together with earlier human D4 structure, revealed an extended binding pocket in addition to the orthosteric pocket. The structure also explained the subtype selectivity of L745870 as this ligand inserted into the extended binding pocket formed by helices II and III in D4, in contrast to a different extended pocket in D2/D3. Using the cpGFP-fusion assay combined with mutagenesis study, the author proposed a reasonable antagonism mechanism of L745870. A unique feature is that they found the structure is a non-symmetric dimer in crystal and tried to verify it in solution. While there are still debates about the dimeric conformation and necessity of GPCR, but it is surely meaningful to see and discuss this non-symmetric conformation. In summary, this paper reveals the ligand selectivity among different dopamine receptors and also shows how L745870 series ligands can inhibit receptor activity.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Crystal structure of dopamine receptor D4 bound to the subtype-selective ligand, L745870: selectivity and antagonism&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Olga Boudker as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Zhi-Jie Liu (Reviewer #1).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The cross-linking study should be conducted while proteins are on the cell membrane as this will mimic and trap the physiological non-symmetry dimer; in contrast, proteins in detergent micelle may be linked by glutaraldehyde artificially. Alternatively, the author may add a monomeric GPCR as negative control with the current method. What are the cross-linkable residues on the identified dimer interface that may be responsible for Figure 3—figure supplement 1?</p><p>2) Is there a pharmacological study comparing the efficiency of ligand L745870 against mouse and human D4 receptor? Can we get some clue based on the current crystal structure and sequence alignment between human and mouse? Since the human D4 structure is also available is it possible to discuss how ligand potency for either L745870 or other ligands can be improved?</p><p>3) Based on Figure 1—figure supplement 1, L745870 appears to have lost significant potency on the engineered constructs. The results in that figure are difficult to interpret, as &quot;L-7&quot; was always in micromolar range. Some routine molecular pharmacology, such as radioligand binding or functional assays would help to convincingly confirm that the crystallization construct retains high affinity for L745870.</p><p>4) The structure is of relatively low resolution (3.5 Å), how did the authors determine and confirm the orientation of L745870, which has a linear shape, in the binding site? Some simple molecular dynamics simulations showing the stability of the binding pose would strengthen the argument, especially given that Figure 1C shows L745870 may have different binding poses in Mol-A and Mol-B.</p><p>5) While the analysis recapitulates previously identified TM2 and TM3 micro-patch on receptor side, it is not clear why L745870 has much higher affinity for DRD4 than for DRD3 and DRD2 on the ligand side, or why L745870 is selective but nemonapride is not, as nemonapride protrudes into the EBP shown in Figure 2E as well. Either more discussion or more analysis is warranted to further elaborate this point.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.48822.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The cross-linking study should be conducted while proteins are on the cell membrane as this will mimic and trap the physiological non-symmetry dimer; in contrast, proteins in detergent micelle may be linked by glutaraldehyde artificially. Alternatively, the author may add a monomeric GPCR as negative control with the current method. What are the cross-linkable residues on the identified dimer interface that may be responsible for Figure 3—figure supplement 1?</p></disp-quote><p>We thank the reviewers’ suggestion. It would be more solid if we could confirm the dimer state in the in vivo environment. In fact, we did try to perform the crosslinking experiment in the cell membrane. However, the results were less clean than just in the presence of detergent; higher order aggregation and oligomerization existed after trying different concentrations of crosslinking agents. Based on our crystal structure, the most probable crosslinking sites in the detergent environment include Arg376 on Helix 8 of protomer A, and Arg216, Arg215 on the cytosol side of TM5 from protomer B.</p><disp-quote content-type="editor-comment"><p>2) Is there a pharmacological study comparing the efficiency of ligand L745870 against mouse and human D4 receptor? Can we get some clue based on the current crystal structure and sequence alignment between human and mouse? Since the human D4 structure is also available is it possible to discuss how ligand potency for either L745870 or other ligands can be improved?</p></disp-quote><p>A previous study (Patel et al., 1997) showed that there was no significant species difference in terms of affinity of L-745,870 towards the human and rodent D4 receptors, which is consistent with the sequence conservation and structure alignment. Meanwhile, most of the pharmaceutical evaluation of L-745,870 was performed in rodents. As one of the ligands of highest selective affinity towards D4 receptors and behaving well in pharmacokinetic trials, L-745870 remains to be a potential drug for clinic use though it failed in treating schizophrenia. New clinic trials are conducted for other disease recently. The drug design question is addressed together with “Question 5”.</p><disp-quote content-type="editor-comment"><p>3) Based on Figure 1—figure supplement 1, L745870 appears to have lost significant potency on the engineered constructs. The results in that figure are difficult to interpret, as &quot;L-7&quot; was always in micromolar range. Some routine molecular pharmacology, such as radioligand binding or functional assays would help to convincingly confirm that the crystallization construct retains high affinity for L745870.</p></disp-quote><p>Compared with radio-ligand binding, the fluorescence assay showed lower signal noise ratio and was used mainly for large scale qualitative analyses. In this assay, fluorescence signals came from dopamine binding towards the engineered GFP-D4 receptor, and the antagonists were added afterwards to the same basin. Due to the limited fluorescing window of the GFP component, the change of signal should be recorded in a short time. Therefore, relatively high concentrations of competitive ligands were used. However, the binding affinity of L745870 towards the engineered receptors likely remains high, since L745870 was able to rapidly replace dopamine in the fluorescence assay, and was required (at a concentration higher than 50 nM) for successful crystallization.</p><disp-quote content-type="editor-comment"><p>4) The structure is of relatively low resolution (3.5 Å), how did the authors determine and confirm the orientation of L745870, which has a linear shape, in the binding site? Some simple molecular dynamics simulations showing the stability of the binding pose would strengthen the argument, especially given that Figure 1C shows L745870 may have different binding poses in Mol-A and Mol-B.</p></disp-quote><p>Thanks the reviewers for this good suggestion. Indeed, L745870 in its free form may assume multiple stereo-chemical conformations, as being confirmed by the programs PHENIX (Liebschner et al., 2019) and Schrodinger (Friesner et al., 2006). However, Asp112 of the receptor is most likely to form a hydrogen bond with proton-titratable amine group in L745870 during the binding, which strongly restricts the freedom of ligand docking. Accordingly, previous analyses (Kortagere et al., 2004; Thal et al., 2016) have proposed a binding mode similar to our refined model. Nevertheless, we are aware that it is possible that the proton-titratable amine group in L745870 occurs in either the 1<italic>H</italic>-pyrrolo[2,3-<italic>b</italic>]pyridine side or chlorophenyl side with micro-environment changing. The difference of ligand density between the two protomers appears to be consistent with this possibility.</p><disp-quote content-type="editor-comment"><p>5) While the analysis recapitulates previously identified TM2 and TM3 micro-patch on receptor side, it is not clear why L745870 has much higher affinity for DRD4 than for DRD3 and DRD2 on the ligand side, or why L745870 is selective but nemonapride is not, as nemonapride protrudes into the EBP shown in Figure 2E as well. Either more discussion or more analysis is warranted to further elaborate this point.</p></disp-quote><p>We thank the reviewers for raising this interesting question. Further discussion is added to the related part in Discussion (second paragraph).</p><p>Reference:</p><p>Liebschner, D., et al., Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol, 2019. 75(Pt 10): p. 861-877.</p></body></sub-article></article>